CHANGCHUN, China and LOS ANGELES, Feb. 4 /PRNewswire-Asia/ -- China Yongxin Pharmaceutical, Inc. (OTC Bulletin Board: CYXN) (the Company), one of the fastest growing, vertically-integrated health products companies in China, today announced it has engaged Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), as the Company's financial advisor to develop financing options in support of the Company's growth plan and provide guidance on meeting listing standards with NASDAQ or AMEX.
According to Mr. Yongxin Liu, the Company's Chairman and CEO, "We are very excited to work closely with Rodman and Renshaw, as it is one the world's preeminent investment banks and will immediately give Yongxin Pharmaceuticals' broad spectrum of healthcare services world recognition."
About China Yongxin Pharmaceuticals, Inc.
Founded in 1993, China Yongxin Pharmaceutical is a manufacturer, retailer and distributor of Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment in Northeastern China. Its retail operations began in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing drug retailers in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit http://www.yongxinchina.com .
About Rodman & Renshaw
Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC.
Rodman & Renshaw, LLC is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information visit Rodman & Renshaw on the Internet at http://www.rodm.com .
Forward Looking Statements
This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," "project", "expect" and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.
For more information, please contact:
CORPORATE:
China Yongxin Pharmaceuticals, Inc.
Sam Liu, COO
Tel: +1-626-581-9098
Email: info@yongxinchina.com
INVESTOR RELATIONS:
Strategic Growth International, Inc.
Richard Cooper, Chairman, or
Linda Ni, Account Executive
Tel: +1-212-838-1444
Email: rcooper@sgi-ir.com; lni@sgi-ir.com
